June 2, 2021
Elena Vasileva, student of Lomonosov Moscow State University (MSU) has developed her diploma thesis in InSysBio and successfully passed its defense. Her diploma thesis entitled “Optimization of anti-CD47 therapeutic agent dosage using PK/PD modeling” was supervised by Oleg Demin Jr, Head of Oncology and Immuno-Oncology at InSysBio. It’s worth highlighting that Elena Vasileva and Oleg Demin Jr prepared the poster “Prediction of target receptor occupancy for ALX148, a CD47 blocker, using mechanistic PK/RO modeling” based on the diploma thesis and presented it in frames of AACR 2020 (American Association for Cancer Research Annual Meeting) and ACoP11! However, they are continuing to develop the subject with another poster presentation.
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 120 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | October 2030 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
|
6
| |
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
|
14
|
15
|
16
|
17
|
18
|
19
|
20
|
|
21
|
22
|
23
|
24
|
25
|
26
|
27
|
|
28
|
29
|
30
|
31
| |||
Thank you for your message! We will get back to you shortly.
